Clinical Trial

Ganoderma Spores Modulate the Gut-Brain Axis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 12, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g/day) or matched placebo.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07524777
Lead Sponsor Ling Zhiqiang
Conditions Depression, Thyroid Cancer
Enrollment 300 participants
Start Date 2026-04-11
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12